PARSIFAL
STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PALBOCICLIB IN COMBINATION WITH FULVESTRANT OR LETROZOLE IN PATIENTS WITH ER+, HER2- LOCALLY ADVANCED OR METASTATIC BREAST CANCER.
CLINICAL TRIAL DETAILS
A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE II TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PALBOCICLIB IN COMBINATION WITH FULVESTRANT OR LETROZOLE IN PATIENTS WITH HER2 NEGATIVE, ER+ METASTATIC BREAST CANCER.
THIS IS AN INTERNATIONAL, RANDOMIZED, OPEN-LABEL, CONTROLLED, MULTICENTER PHASE II CLINICAL TRIAL TO INVESTIGATE AND COMPARE THE SAFETY AND EFFICACY OF PALBOCICLIB COMBINED WITH FULVESTRANT OR LETROZOLE IN WOMEN WITH ER+, HER2- LOCALLY ADVANCED OR METASTATIC BREAST CANCER.
COUNTRY
STATUS
TUMOR TYPE
PHASE
N
SITES
HR+ HER2neg ABC
50
486
II
Spain, France, Italy, UK, Germany, Russia, Czech Republic
Closing
TRIAL OVERVIEW
PRESS RELEASE
SCIENTIFIC IMPACT
SABCS 2023 PARSIFAL-LONG substudy presentation
SABCS 2023 PARSIFAL-LONG substudy lay summary
SABCS 2023 DNADX PARSIFAL substudy poster
SABCS 2023 DNADX PARSIFAL substudy lay summary
BLOG ARTICLES RELATED
Spotlight - LUPER small-cell lung cancer trial
It was great to be back at ASCO!
We’re presenting at ASCO 2022!
PARSIFAL: Identifying an endocrine agent for palbociclib in endocrine sensitive ABC
Interview with Dr. Llombart on OncologyTube on the PARSIFAL and BIOPER studies presented at SABCS
Final safety results of our PARSIFAL study were presented at SABCS 2020
SABCS 2020: Final results of PARSIFAL and BIOPER clinical trials to be presented
Results of the PARSIFAL study to be presented at the SEOM Conference 2020
SEOM 2020\: Results from the Spanish cohort of the MEDSIR-sponsored study PARSIFAL
PARSIFAL clinical trial results presented at ASCO Annual Meeting
MedSIR to present results of clinical trials PHERGain and PARSIFAL at ASCO 2020
Last Patient Last Visit for Final Analysis in PARSIFAL Study!
TRIAL SITES